Yinghui Zhou

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models

Jose F. Ponte, Olga Ab, Leanne Lanieri et al. · Neoplasia · 2016 · 112 citations · Full text

Medicine, Oncology, Pharmacology +16

Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

Benedetta Pellegrino, Andrea Herencia-Ropero, Alba Llop‐Guevara et al. · Cancer Research · 2022 · 97 citations · Full text

Medicine, Genetics, Oncology +15

Chimeric mouse tumor models reveal differences in pathway activation between ERBB family– and KRAS-dependent lung adenocarcinomas

Yinghui Zhou, William M. Rideout, Tong Zi et al. · Nature Biotechnology · 2009 · 86 citations

Medicine, Molecular Biology, Oncology +13

TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.

Shaveta Vinayak, Sara M. Tolaney, Lee S. Schwartzberg et al. · Journal of Clinical Oncology · 2018 · 77 citations

Medicine, Oncology, Pharmacology +15

Pri-miR-124 rs531564 and pri-miR-34b/c rs4938723 Polymorphisms Are Associated with Decreased Risk of Esophageal Squamous Cell Carcinoma in Chinese Populations

Junjie Zhang, Xuewen Huang, Juanjuan Xiao et al. · PLoS ONE · 2014 · 68 citations · Full text

Medicine, Genetics, Oncology +17